SCHEMBL2838664

SCHEMBL2838664

O=C(O)NCCc1cc(Sc2ccc(Cl)nc2)n(-c2ccccc2Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SLC16A3 O15427 3/20 0.35
SLC16A1 P53985 3/20 0.35
MAPT P10636 1/20 0.34
HSD11B1 P28845 1/20 0.34
CNR1 P21554 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DGAT1 O75907 1/20 0.33
RIPK1 Q13546 1/20 0.32
HIF1A Q16665 1/20 0.32
PDE4B Q07343 1/20 0.32
USP2 O75604 1/20 0.32
GLA P06280 1/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123630 0.91 MDM2 (0.38) SMN1; SMN2NPC1RAB9ADGAT1RIPK1
SCHEMBL4123908 0.91 SMN1; SMN2 (0.37) SMN1; SMN2NPC1RAB9AL3MBTL1DGAT1
SCHEMBL4136940 0.88 KCNQ3 (0.34) SMN1; SMN2NPC1RAB9ACNR1P2RX7
SCHEMBL4126946 0.87 KCNQ3 (0.35) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4127374 0.87 SCN9A (0.37) SMN1; SMN2NPC1RAB9ACNR1RIPK1
SCHEMBL4135601 0.87 SMN1; SMN2 (0.34) SMN1; SMN2NPC1RAB9ADGAT1RIPK1
SCHEMBL4128953 0.86 P2RX7 (0.37) SMN1; SMN2NPC1RAB9ASLC16A3SLC16A1
SCHEMBL4118494 0.86 SMN1; SMN2 (0.33) SMN1; SMN2NPC1RAB9ADGAT1RIPK1
SCHEMBL3708990 0.85 P2RX7 (0.39) SMN1; SMN2RAB9ASLC16A3SLC16A1MAPT
SCHEMBL4140877 0.85 SLC16A3 (0.38) SMN1; SMN2SLC16A3SLC16A1MAPTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
EP-2196459-B1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-02 EP disclosed
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 SMN1; SMN2 4327/4885NPC1 53/4885RAB9A 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.